Analysys, a Beijing-based data analytics company, revealed in its latest research report that the industrialization of the AI healthcare market in China is accelerating.
The company stated that the AI healthcare market is expected to reach approximately 106 billion yuan (1 yuan = Rp2,419) or approximately US$15 billion (1 US$ = Rp16,871) by 2024, with this growth driven by transformative advances in AI technology and intelligent hardware.
Based on its analysis, the application of AI in high-value scenarios, such as tumor screening and chronic disease management, is expected to be a growth engine for the industry in the next three years.
China Securities, a leading securities firm, also highlighted the promising market and investment prospects for AI healthcare in a series of recently published market analyses.
In a research note, China Securities specifically attributed the growing momentum in the AI healthcare sector to policy support, citing a national target announced by the government in April 2025 to develop more than 100 typical scenarios where digital intelligence technology will be applied in the pharmaceutical industry by 2027.
One notable example is the plan released last month by the Beijing Municipal Health Commission, which targets widespread adoption of AI in medical institutions by 2027, a move expected to be emulated by other regions, according to China Securities research.
In a January research report, CITIC Securities, another securities firm, highlighted a fundamental shift in the commercialization of AI healthcare in China, which this year showed a clearer path as payment mechanisms for AI medical solutions strengthened and payers became more identified.
According to the report, government policies are driving market demand. A guideline released by China's National Healthcare Security Administration (NHSA) last year incorporated AI-assisted diagnosis into the national pricing framework for pathology, allowing public health insurance to directly reimburse AI-assisted medical solutions. This move, according to the report, has unlocked substantial commercial potential for AI pathology.
The report also noted that many regions in China, including Beijing and Shanghai, as well as Zhejiang and Guangdong provinces, are accelerating the adoption of AI healthcare, with government-supported pilot bases already established.
Furthermore, CITIC Securities highlighted five potential investment areas, including the development of AI-based medicine, AI solutions for grassroots healthcare, medical data circulation and transaction, AI-assisted pathology diagnostics, and the expansion of AI healthcare models to the consumer market.
Investments by major companies in healthcare AI models, such as PANDA, an AI platform developed by Alibaba's Damo Academy, and Ant Afu, an AI health management app for users, are strengthening the capacity of these models and driving deeper commercialization of healthcare AI.
